Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Research & Development (2016 - 2025)

Fennec Pharmaceuticals' Research & Development history spans 15 years, with the latest figure at $20000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 60.0% year-over-year to $20000.0, compared with a TTM value of $250000.0 through Dec 2025, down 18.57%, and an annual FY2025 reading of $250000.0, down 18.57% over the prior year.
  • Research & Development for Q4 2025 was $20000.0 at Fennec Pharmaceuticals, down from $29000.0 in the prior quarter.
  • The five-year high for Research & Development was $2.4 million in Q1 2021, with the low at $3000.0 in Q1 2024.
  • Average Research & Development over 5 years is $452736.8, with a median of $97000.0 recorded in 2024.
  • Year-over-year, Research & Development tumbled 99.72% in 2023 and then skyrocketed 3033.33% in 2025.
  • Tracing FENC's Research & Development over 5 years: stood at $1.2 million in 2021, then tumbled by 90.58% to $117000.0 in 2022, then tumbled by 72.65% to $32000.0 in 2023, then soared by 56.25% to $50000.0 in 2024, then plummeted by 60.0% to $20000.0 in 2025.
  • Per Business Quant, the three most recent readings for FENC's Research & Development are $20000.0 (Q4 2025), $29000.0 (Q3 2025), and $107000.0 (Q2 2025).